Safety Trial of Naproxen Sodium/ Diphenhydramine
Condition: Pain
Intervention: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111); Placebo
Intervention description: 2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days; 2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
Intervention MeSH terms: Naproxen
Phase: Phase 3
Study type: Interventional
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 326.0
Sex: All
Minimum age: 12 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Maximum Use Safety Trial

Summary:

      The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and
      diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to
      placebo (capsules containing no drug) when taken for 10 days.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Healthy, ambulatory, male and female volunteers ages 12 and older

          -  History of experiencing occasional sleeplessness accompanied by aches and pains at
             least two times, but not continually for more than 14 days per month, in at least 2 of
             the past 3 months

          -  Female subjects of childbearing potential must be using a medically acceptable form of
             birth control, e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®,
             for at least 1 month prior to screening (3 months on oral contraceptives), or
             double-barrier and have a negative pregnancy test at Screening. Female subjects of
             nonchildbearing potential must be amenorrheic for at least 2 years or have had a
             hysterectomy and/or bilateral oophorectomy

          -  Be willing and able to participate in all scheduled visits, treatment plan, tests and
             other trial procedures according to the protocol

          -  Provide a personally signed and dated informed consent indicating that the subject has
             been informed of all pertinent aspects of the trial, (subjects <18 years of age must
             sign a written assent and have parental or guardian consent).

        Exclusion Criteria:

          -  History of hypersensitivity to naproxen sodium, acetaminophen, or any NSAIDs
             (Nonsteroidal Antiinflammatory Drugs), diphenhydramine or any other antihistamines,
             and similar pharmacological agents or components of the product

          -  Evidence or history of clinically significant (in the judgment of the investigator)
             hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,
             psychiatric, neurologic diseases, or malignancies with the last 5 years

          -  A history of a chronic or severe sleep problem which does not respond to OTC
             (Over-the-counter) medication and/or requires a prescription hypnotic or sedative

          -  Currently experiencing chronic pain or on chronic NSAID therapy (defined as taking a
             daily [5 to 7 days per week] regimen of prescription or OTC NSAIDs)

          -  Current or past history of gastrointestinal ulcers or bleeding or other bleeding
             disorders

          -  Use of any OTC or prescription medications with which the administration of naproxen,
             acetaminophen, or any NSAIDs, diphenhydramine or any other antihistamines or
             sedatives, is contraindicated

          -  Chronic use of other products containing diphenhydramine, including topical products

          -  Use of steroids or blood thinning (anticoagulant) drugs (aspirin 81 mg is permitted if
             the dose has been taken for at least one month prior to screening)